1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

NDPHARM

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

1998

Location

Nanjing Jiangsu China

Primary Industry

Pharmaceuticals

About

Established in 1998 and based in Nanjing, China, NDPHARM is a medical injectable drug development company specializing in the development, manufacture and marketing of injectable urokinase and small molecule heparin sodium APIs. In July 2022, the company raised an undisclosed amount of strategic funding from new investor Jiangsu Aidea Pharmaceutical Co., Ltd. The company's main business is the development, manufacture and marketing of injectable urokinase and small molecule heparin sodium APIs. The company self-developed products include povidone-iodine solution, nifurtimox vaginal ointment, povidone-iodine suppository, thrombin lyophilized powder, water-soluble vitamin for injection, oxytetracycline sodium for injection and urokinase for injection.
Current Investors
Jiangsu Investment Management, Nanjing Public Utilities Development, Jiangsu Aidea Pharmaceutical Co., Ltd.

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.ndpharm.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.